RNS Number:0781Z
Corin Group PLC
25 July 2002




                                CORIN GROUP PLC

                           ("Corin" or "the Company")

                      STATEMENT AT ANNUAL GENERAL MEETING

Corin is a developer, manufacturer and distributor of a wide range of
reconstructive orthopaedic devices, predominantly hips and knees.  In May 2002,
Corin was successfully floated on the full list of the London Stock Exchange.

At today's Annual General Meeting, Peter Gibson, Corin's Executive Chairman,
will make the following statement:

"I am pleased to report that trading for the first half of 2002 (January to
June) has been in line with expectations.  Full interim results for the period
will be announced on Tuesday 24 September 2002.

In the UK, Corin's domestic market, sales in the first half of 2002 were robust,
primarily driven by on-going sales growth in Cormet 2000.  The Cormet and
Rotaglide instructional courses continue to be well accepted and provide an
excellent platform for encouraging new users of this important technology.

Corin USA has had a strong start to the year, with sales and earnings above
budget and substantially above the prior year.  The principal product
contributor is the Trinity Polyaxial Spinal System, which gained FDA approval in
April 2001 and was launched in the United States in July 2001.  Sales of the
Cormet 2000 Metal-on-Metal Resurfacing Hip System, through an "FDA clinical
trial", are in line with forecasts and are also making a substantial
contribution to Corin USA's sales growth.  The Rotaglide+ FDA approved clinical
trial has progressed at a slower rate than the Cormet trial, but is anticipated
to accelerate in the second part of 2002.  Both Cormet and Rotaglide trials are
anticipated to be complete by 2003, with full approval in 2006, as described in
the Company's flotation Prospectus.

During the first half of 2002, the Company has strengthened its sales management
focus on Continental Europe and we expect to achieve satisfactory growth from
this strategically important market by the end of the current year.

Corin Japan has enjoyed a strong first half of 2002, with sales and earnings
ahead of both budget and the prior year.

As described above, Cormet 2000 Metal-on-Metal Resurfacing continues to grow
rapidly, with increasing surgical acceptance of its benefit to the young, active
arthritic.  The recent endorsement by the National Institute for Clinical
Excellence of metal on metal hip resurfacing was a significant milestone and
should lead to an uplift in sales in the longer term. In the early part of 2002,
Corin launched its Large Diameter Metal-on-Metal Stemmed Hip Arthroplasty
System, significantly expanding the surgical application of metal-on-metal
arthroplasty.  Corin has also recently received confirmation that certain of its
patent applications in the UK and Europe, describing this technology, have been
approved.

The programme of conversion from Rotaglide to the Rotaglide+ Total Knee System
is on target and will be essentially complete by the end of 2002.  Corin sales
of total knees continue to show satisfactory year-on-year growth.

The Trinity Polyaxial System's principal market to-date has been, as described
above, primarily the United States.   In the second half of 2002, the Trinity
Polyaxial Pedicular Screw System will be progressively introduced into other
markets, including the UK, France and Spain. Sales of the Trinity Polyaxial
System have already commenced in Korea.

In conclusion, we confidently expect the first half of 2002 to be reported in
line with market expectation."



                                                                    25 July 2002



ENQUIRIES:

Corin Group Plc                                       Tel. 01285 659866
Peter Gibson, Executive Chairman

College Hill                                          Tel. 0207 457 2020
Archie Berens                                         (Mobile: 07802 442486)
Clare Warren                                          (Mobile: 07050 149642)






                      This information is provided by RNS
            The company news service from the London Stock Exchange